25-Sep-2026
Globe Newswire (Thu, 24-Sep 8:44 AM ET)
Lantheus gains approval of Bravnesta, generic competitor to Lutathera
Seeking Alpha News (Tue, 22-Sep 10:39 AM ET)
Globe Newswire (Tue, 22-Sep 8:00 AM ET)
Lantheus withdraws, resubmits HSR filing for Curium acquisition
Seeking Alpha News (Mon, 21-Sep 5:35 PM ET)
Lantheus Merger Advances with Renewed Antitrust Review
TipRanks (Mon, 21-Sep 4:59 PM ET)
Are LNTH, ITGR, CZR Obtaining Fair Deals for their Shareholders?
PRNewswire (Fri, 11-Sep 12:28 PM ET)
Business Wire (Thu, 10-Sep 4:18 PM ET)
Business Wire (Sat, 29-Aug 7:41 AM ET)
Globe Newswire (Fri, 14-Aug 8:00 AM ET)
Globe Newswire (Tue, 11-Aug 9:16 AM ET)
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
Lantheus Holdings trades on the NASDAQ stock market under the symbol LNTH.
As of September 25, 2026, LNTH stock price climbed to $99.74 with 806,350 million shares trading.
LNTH has a beta of 0.51, meaning it tends to be less sensitive to market movements. LNTH has a correlation of 0.04 to the broad based SPY ETF.
LNTH has a market cap of $6.51 billion. This is considered a Mid Cap stock.
Last quarter Lantheus Holdings reported $388 million in Revenue and $1.55 earnings per share. This beat revenue expectation by $24 million and exceeded earnings estimates by $.29.
In the last 3 years, LNTH traded as high as $126.89 and as low as $47.25.
The top ETF exchange traded funds that LNTH belongs to (by Net Assets): AVUV, IJH, VTI, IWM, VB.
LNTH has outperformed the market in the last year with a return of +93.8%, while the SPY ETF gained +18.4%. However, in the most recent history, LNTH shares have underperformed the stock market with its stock returning -8.5% in the last 3 month period and -0.5% for the last 2 week period, while SPY has returned +5.3% and +1.2%, respectively.
LNTH support price is $99.42 and resistance is $100.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LNTH shares will trade within this expected range on the day.